Skip to content

Zymeworks ZYME Total debt

Total debt at other companies

AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
$13.61K-99.9%
AbCellera Biologics Inc. logo
AbCellera Biologics Inc.ABCL
$140.18M+107%
Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN
$36.83M+59.4%
Stoke Therapeutics, Inc. logo
Stoke Therapeutics, Inc.STOK
$3.42M-42.5%
Pfizer logo
PfizerPFE
Amgen logo
AmgenAMGN

Other financials

Income statement

See full
Revenue$2.4M-91.1%
Operating income-$47.1M-84.0%
Net income-$44.2M-95.1%
EPS (diluted)-$0.59-96.7%

Balance sheet

See full
Cash & equivalents$244.3M+221%
Total equity$163.6M-49.7%
Total assets$478.2M+12.4%

Cash flow

See full
Operating cash flow-$45.7M-1,242%
CapEx$216.0K+1,250%
Free cash flow-$45.9M-1,242%

Valuation

See full
Market cap$1.76B+125%
Enterprise value$1.53B+112%
P/S21.6×+13.2×

Profitability

See full
Operating margin-140.4%+7.3pp
Net margin-126.3%+5.0pp
FCF margin-94.8%+15.5pp

Returns & leverage

See full
Return on equity-42%+29.2pp
Debt / equity0.1×0.0×
Current ratio10.8×+6.1×

Where this comes from

Computed from long term debt + current portion long term debt + short term borrowings + operating lease liabilities + finance lease liabilities + financing obligations: $17.04M.

The official record: Zymeworks’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Zymeworks's total debt.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Zymeworks's total debt?
Zymeworks (ZYME) reported total debt of $17.04M in Q1 2026.
How has Zymeworks's total debt changed year-over-year?
Zymeworks's total debt decreased by 7.7% year-over-year, from $18.47M to $17.04M.
What is the long-term trend for Zymeworks's total debt?
Over 4 years (2021 to 2025), Zymeworks's total debt has grown at a -13.3% compound annual growth rate (CAGR), from $32.38M to $18.27M.
What does total debt mean?
Total debt represents the aggregate sum of all interest-bearing financial obligations, including short-term borrowings, the current portion of long-term debt, and long-term debt instruments. It also encompasses capitalized lease liabilities and other debt-like financing arrangements that require fixed repayment schedules. This metric serves as a comprehensive indicator of a company's total financial leverage and its reliance on external capital providers.